Navigation Links
Liquid ventilation

To live we need to breathe. Prior to being born we carry this activity out through the placenta and subsequently by means of our lungs. In normal development, the lungs of the foetus are filled with amniotic liquid and, on being born, the first cry activates this respiration surface. But the main problem that premature babies have is that their lungs are not well formed. Moreover, they often lack surfactant, a compound formed by proteins and lipids that avoids the lungs folding in on themselves before the baby gets stronger.

The respirators usually employd in these cases provide artificial surfactant, but not always in sufficient amounts to provide correct therapy. In order to alleviate this situation, the Nautical School at the University of the Basque Country has developed a liquid respiration respirator.

The machine simulates placentary respiration by filling the lungs of the premature baby with liquid and then the respirator introduces and extracts the required quantity of liquid at a suitable respiratory rhythm. The amount of liquid administered is usually in the order of 10 millilitres per kilogram of the baby's weight.

Perfluorocarbons instead of air

Perfluorocarbon is used in liquid respiration, as it has a suitable surface tension in order to maintain the pulmonary structure and the fluorine has good properties for the transport of and interchange between blood and the gases, O2 and CO2. The respirator syringes introduce the oxygenated perfluorocarbon to the very last alveola. Here oxygen is released and carbon dioxide taken up in the same way as on the respiration surface. Then the respirator extracts part of the perfluorocarbon from the lungs and introduces the next oxygenated dose. The same machine carries out the removal of CO2 from the perfluorocarbon and adds oxygen to it.

Being full of liquid, the problems of pressure associated with conventional assisted respiration are avoided because the lungs of the premature baby suffer less stress and respire more easily.

However, this story does not have a happy ending. The respirator, for the moment, is no more than a prototype. In the experiments carried out at the Cruces hospital in Bilbao with artificial lungs and with animals, the results have been very good. It has even been applied successfully in more than 80 death-threatening situations in premature babies. But the perfluorocarbon for medical use is not available on the market. As premature babies need very small quantities and no commercial application for adults has been found, the patent-owning company has opted not to market it arguing that it lacks profitability. Thus, an industrial version of the liquid respirator is yet to be developed


'"/>

Source:Elhuyar Fundazioa


Related biology news :

1. Liquid crystals show promise in controlling embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... $7M Series B financing, adding an additional $3M from ... by Mesa Verde Venture Partners and other strategic partners ... directed towards further accelerating commercial adoption of their flagship ... test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
Breaking Biology Technology: